BRPI1015569A2 - compostos úteis para o tratamento de doenças degenerativas e inflamatórias. - Google Patents

compostos úteis para o tratamento de doenças degenerativas e inflamatórias.

Info

Publication number: BRPI1015569A2
Authority: BR; Brazil
Prior art keywords: degenerative; treatment; inflammatory diseases; compounds useful; compounds
Prior art date: 2009-06-26

Application number

BRPI1015569A

Other languages

English (en)

Inventor

Christel Jeanne Marie Menet

Koen Kurt Smits

Original Assignee

Galapagos Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-26

Filing date

2010-06-25

Publication date

2016-08-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015569(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-06-25 Application filed by Galapagos Nv filed Critical Galapagos Nv

2016-08-16 Publication of BRPI1015569A2 publication Critical patent/BRPI1015569A2/pt

2020-10-27 Publication of BRPI1015569B1 publication Critical patent/BRPI1015569B1/pt

2021-05-25 Publication of BRPI1015569B8 publication Critical patent/BRPI1015569B8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI1015569A 2009-06-26 2010-06-25 compostos úteis para o tratamento de doenças degenerativas e inflamatórias BRPI1015569B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US22068809P	2009-06-26	2009-06-26
US61/220,688		2009-06-26
PCT/EP2010/059064 WO2010149769A1 (en)	2009-06-26	2010-06-25	5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors

Publications (3)

Publication Number	Publication Date
BRPI1015569A2 true BRPI1015569A2 (pt)	2016-08-16
BRPI1015569B1 BRPI1015569B1 (pt)	2020-10-27
BRPI1015569B8 BRPI1015569B8 (pt)	2021-05-25

Family

ID=42562363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1015569A BRPI1015569B8 (pt)	2009-06-26	2010-06-25	compostos úteis para o tratamento de doenças degenerativas e inflamatórias

Country Status (43)

Country	Link
US (9)	US8088764B2 (pt)
EP (2)	EP2445911B1 (pt)
JP (2)	JP5591925B2 (pt)
KR (3)	KR101696669B1 (pt)
CN (2)	CN104262337A (pt)
AR (1)	AR077220A1 (pt)
AU (3)	AU2010264633B2 (pt)
BR (1)	BRPI1015569B8 (pt)
CA (1)	CA2765985C (pt)
CL (1)	CL2011003247A1 (pt)
CO (1)	CO6491040A2 (pt)
CR (1)	CR20120016A (pt)
CY (3)	CY1119214T1 (pt)
DK (2)	DK3178819T3 (pt)
DO (1)	DOP2011000388A (pt)
EA (1)	EA021637B1 (pt)
EC (1)	ECSP12011626A (pt)
ES (2)	ES2626908T3 (pt)
FR (1)	FR21C1011I2 (pt)
GB (1)	GB2483424B (pt)
HR (2)	HRP20170826T1 (pt)
HU (3)	HUE033154T2 (pt)
IL (1)	IL216667A (pt)
LT (3)	LT2445911T (pt)
MA (1)	MA33448B1 (pt)
ME (1)	ME02699B (pt)
MX (1)	MX344951B (pt)
MY (1)	MY156664A (pt)
NI (1)	NI201100222A (pt)
NL (1)	NL301096I2 (pt)
NO (1)	NO2021013I1 (pt)
NZ (1)	NZ596838A (pt)
PE (1)	PE20121032A1 (pt)
PL (2)	PL2445911T3 (pt)
PT (2)	PT2445911T (pt)
RS (1)	RS56035B1 (pt)
SG (2)	SG10201703497YA (pt)
SI (2)	SI3178819T1 (pt)
SM (1)	SMT201700265T1 (pt)
TW (1)	TWI462920B (pt)
UA (1)	UA107935C2 (pt)
WO (1)	WO2010149769A1 (pt)
ZA (1)	ZA201109386B (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3041B1 (ar)	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) *	2009-06-26	2014-12-01	葛萊伯格有限公司	用於治療退化性及發炎疾病之新穎化合物
US8871184B2 (en)	2009-10-02	2014-10-28	Foamix Ltd.	Topical tetracycline compositions
EP2343294A1 (en)	2009-11-30	2011-07-13	Bayer Schering Pharma AG	Substituted triazolopyridines
AR086042A1 (es) *	2011-04-28	2013-11-13	Galapagos Nv	Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
EP2770992A4 (en) *	2011-10-26	2015-12-30	Emily A Stein	AGENTS, METHODS AND DEVICES FOR AFFECTING NERVOUS FUNCTION
WO2013173506A2 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
DK2863950T3 (en) *	2012-06-22	2018-09-03	Galapagos Nv	AMINOTRIAZOLOPYRIDINE USED IN THE TREATMENT OF INFLAMMATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
GB201302036D0 (en) *	2013-02-05	2013-03-20	Queen Mary & Westfield College	Diagnosis
EP3079694A1 (en) *	2013-12-11	2016-10-19	Cephalon, Inc.	Treatment of multiple sclerosis with a 1,2,4-triazolo [1,5a]pyridine derivative
GB201402070D0 (en)	2014-02-07	2014-03-26	Galapagos Nv	Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) *	2014-02-07	2014-03-26	Galapagos Nv	Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TWI679205B (zh)	2014-09-02	2019-12-11	日商日本新藥股份有限公司	吡唑并噻唑化合物及醫藥
MA41252A (fr)	2014-12-23	2017-10-31	Gilead Sciences Inc	Formes solides d'un inhibiteur d'ask 1
SG11201708181RA (en)	2015-04-13	2017-11-29	Galapagos Nv	Methods for the treatment of inflammatory disorders
AU2016248727B2 (en)	2015-04-13	2021-04-01	Alfasigma S.P.A.	Methods for the treatment of cardiovascular disorders
WO2016179207A1 (en) *	2015-05-05	2016-11-10	Concert Pharmaceuticals, Inc.	Deuterated filgotinib
CN105061420B (zh) *	2015-06-04	2017-09-05	南京旗昌医药科技有限公司	一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) *	2015-07-14	2017-01-11	苏州富士莱医药股份有限公司	一种Filgotinib的合成方法
WO2017012773A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Solid forms of filgotinib free base
WO2017012770A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Acid addition salts of filgotinib
WO2017012771A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Crystalline filgotinib sulfonic acid addition salts
CN105198880B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105111206B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105111207B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105218539B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198877B (zh) *	2015-09-18	2017-09-22	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105198878B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198879B (zh) *	2015-09-18	2017-09-22	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105198876B (zh) *	2015-09-18	2017-09-29	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物h晶型及其制备方法
WO2017106568A1 (en) *	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
WO2017106564A1 (en)	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
US20170174788A1 (en)	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
CN108349974B (zh) *	2016-02-02	2021-04-30	深圳市塔吉瑞生物医药有限公司	一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh)	2016-03-01	2020-12-11	日商日本新藥股份有限公司	具jak抑制作用之化合物之結晶
CN105669669A (zh) *	2016-03-04	2016-06-15	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法
AU2017239301A1 (en) *	2016-03-21	2018-11-08	Crystal Pharmatech Co., Ltd	Crystalline forms of hydrochloride of drug for treating or preventing JAK-associated disease and preparation method thereof
US10071079B2 (en)	2016-06-29	2018-09-11	Bristol-Myers Squibb Company	[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
JP6978097B2 (ja) *	2016-07-26	2021-12-08	スーヂョウロングバイオテックファーマシューティカルズカンパニーリミテッドSuzhou Longbiotech Pharmaceuticals Co., Ltd.	Ｊａｋ阻害剤としての複素環化合物、該化合物の塩類および治療への使用
EA038972B1 (ru)	2016-07-30	2021-11-16	Бристол-Маерс Сквибб Компани	Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
CN107759587B (zh) *	2016-08-19	2021-01-26	中国医药研究开发中心有限公司	[1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
US10398641B2 (en)	2016-09-08	2019-09-03	Foamix Pharmaceuticals Ltd.	Compositions and methods for treating rosacea and acne
MA46188A (fr)	2016-09-09	2019-07-17	Bristol Myers Squibb Co	Composés indole substitués par pyridyle
CN107880038B (zh) *	2016-09-30	2021-09-28	中国医药研究开发中心有限公司	[1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CA3043396A1 (en)	2016-11-10	2018-05-17	Galapagos Nv	Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
EA039344B1 (ru) *	2017-01-19	2022-01-17	Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд.	Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
GB201702603D0 (en)	2017-02-17	2017-04-05	Galápagos Nv	Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar)	2017-03-14	2019-01-30	Gilead Sciences Inc	تركيبات صيدلية تتضمن مثبط jak
ES2909401T3 (es)	2017-08-04	2022-05-06	Bristol Myers Squibb Co	Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9
ES2921020T3 (es)	2017-08-04	2022-08-16	Bristol Myers Squibb Co	Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
US20210253593A1 (en)	2017-11-14	2021-08-19	Bristol-Myers Squibb Company	Substituted indole compounds
MX2020006093A (es)	2017-12-15	2020-08-24	Bristol Myers Squibb Co	Compuestos de indol eter sustituidos.
PE20210129A1 (es)	2017-12-18	2021-01-19	Bristol Myers Squibb Co	Compuestos de 4-azaindol
CN111491930B (zh)	2017-12-19	2023-09-26	百时美施贵宝公司	可用作tlr抑制剂的经取代的吲哚化合物
ES2922174T3 (es)	2017-12-19	2022-09-09	Bristol Myers Squibb Co	Compuestos de indol sustituidos con amida útiles como inhibidores de TLR
BR112020011788A2 (pt)	2017-12-19	2020-11-24	Bristol-Myers Squibb Company	compostos 6-azaindóis
US11299501B2 (en)	2017-12-20	2022-04-12	Bristol-Myers Squibb Company	Diazaindole compounds
JP7291707B2 (ja)	2017-12-20	2023-06-15	ブリストル－マイヤーズスクイブカンパニー	アリールおよびヘテロアリール置換されたインドール化合物
KR102714788B1 (ko)	2017-12-20	2024-10-08	브리스톨-마이어스 스큅 컴퍼니	Tlr 억제제로서 유용한 아미노 인돌 화합물
GB201808575D0 (en)	2018-05-24	2018-07-11	Galapagos Nv	Methods for the treatment of psoriatic arthrits
US10815227B2 (en)	2018-08-27	2020-10-27	Cadila Healthcare Limited	Processes for the preparation of filgotinib
EP3870589B1 (en)	2018-10-24	2023-09-06	Bristol-Myers Squibb Company	Substituted indole dimer compounds
KR102839382B1 (ko)	2018-10-24	2025-07-25	브리스톨-마이어스 스큅 컴퍼니	치환된 인돌 및 인다졸 화합물
CN111154711B (zh) *	2018-11-07	2022-08-05	杭州瑞普晨创科技有限公司	JAK2抑制剂在胰岛β细胞诱导分化中的应用
WO2020177705A1 (zh) *	2019-03-05	2020-09-10	苏州科睿思制药有限公司	Filgotinib的马来酸盐晶型CSI及其制备方法和用途
US12398141B2 (en)	2019-03-14	2025-08-26	Shanghai Synergy Pharmaceutical Sciences Co., Ltd	JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine
JP2022526713A (ja)	2019-03-21	2022-05-26	オンクセオ	がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
MX2021011548A (es)	2019-03-30	2021-10-22	Unichem Lab Ltd	Proceso novedoso para la preparacion de filgotinib e intermediarios del mismo.
EP3965888B1 (en)	2019-05-09	2024-08-21	Bristol-Myers Squibb Company	Substituted benzimidazolone compounds
CN110204542B (zh) *	2019-05-23	2022-05-20	四川伊诺达博医药科技有限公司	一种JAK1抑制剂Filgotinib的合成方法
CN110151738A (zh) *	2019-06-03	2019-08-23	上海基科生物化学有限公司	一种Jak2抑制剂联合虎杖苷雾化剂及其制备方法和应用
WO2021067326A1 (en)	2019-10-01	2021-04-08	Bristol-Myers Squibb Company	Substituted bicyclic heteroaryl compounds
ES2965164T3 (es)	2019-10-04	2024-04-11	Bristol Myers Squibb Co	Compuestos de carbazol sustituidos
IT201900020240A1 (it)	2019-11-04	2021-05-04	Advitech Advisory And Tech Sa	Procedimento per la preparazione di Filgotinib e intermedi di sintesi
JP2023500906A (ja)	2019-11-08	2023-01-11	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
CN110878097B (zh) *	2019-11-29	2021-11-02	杭州科巢生物科技有限公司	菲格替尼的制备方法
CN111072655B (zh) *	2019-12-30	2021-12-10	深圳市坤健创新药物研究院	一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN115066425B (zh) *	2020-02-13	2023-06-23	珠海联邦制药股份有限公司	Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用
ES3037893T3 (en)	2020-02-21	2025-10-07	Zhuhai United Laboratories Co Ltd	Crystalline form of jak inhibitor and application thereof
EP4196477A4 (en) *	2020-08-17	2024-10-09	Vyne Therapeutics Inc.	TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONS
US20230355608A1 (en) *	2020-10-02	2023-11-09	University Of Massachusetts	Targeting polycythemia vera (pv)-initiating cells by blocking leukotriene binding to their receptors
CN115368389A (zh) *	2021-05-19	2022-11-22	奥锐特药业(天津)有限公司	一种Filgotinib中间体的制备方法
CN113773322B (zh) *	2021-11-10	2022-02-11	奥锐特药业(天津)有限公司	一种Filgotinib的制备方法
CN114409675B (zh) *	2022-01-07	2023-08-04	重庆医科大学	螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
CN116496268A (zh) *	2022-01-18	2023-07-28	盛世泰科生物医药技术(苏州)有限公司	一种含环丙酰胺化合物及其应用
WO2023194842A1 (en)	2022-04-05	2023-10-12	Unichem Laboratories Limited	Substituted tricyclic compounds and their use in rheumatoid arthritis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ208996A (en)	1983-07-28	1989-08-29	American Cyanamid Co	5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions
ES2228451T3 (es)	1999-01-29	2005-04-16	Chugai Seiyaku Kabushiki Kaisha	Promotores de condrogenesis y derivados de indolin-2-ona.
US20040138285A1 (en)	2001-04-27	2004-07-15	Makoto Okazaki	Chondrogenesis promoters
US6514989B1 (en) *	2001-07-20	2003-02-04	Hoffmann-La Roche Inc.	Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
EP1601672B1 (en)	2003-02-14	2006-07-26	Pfizer Products Inc.	Triazolo-pyridines as anti-inflammatory compounds
US20050222171A1 (en)	2004-01-22	2005-10-06	Guido Bold	Organic compounds
WO2005124342A2 (en)	2004-06-21	2005-12-29	Galapagos N.V.	Methods and means for treatment of osteoarthritis
JP2008509987A (ja)	2004-08-18	2008-04-03	ファルマシアアンドアップジョンカンパニーリミテッドライアビリティカンパニー	トリアゾロピリジン化合物
JP2008515874A (ja)	2004-10-07	2008-05-15	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	抗菌薬
GB0515026D0 (en)	2005-07-21	2005-08-31	Novartis Ag	Organic compounds
JP5336375B2 (ja)	2006-08-30	2013-11-06	セルゾームリミテッド	キナーゼ阻害剤としてのトリアゾール誘導体
CL2008001626A1 (es)	2007-06-05	2009-06-05	Takeda Pharmaceuticals Co	Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
AR067562A1 (es)	2007-07-18	2009-10-14	Novartis Ag	Compuestos heterociclicos inhibidores de kinasa
WO2009017954A1 (en) *	2007-08-01	2009-02-05	Phenomix Corporation	Inhibitors of jak2 kinase
KR20100075881A (ko)	2007-08-31	2010-07-05	메르크 세로노 에스. 에이.	트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도
GB0719803D0 (en) *	2007-10-10	2007-11-21	Cancer Rec Tech Ltd	Therapeutic compounds and their use
US20100035875A1 (en)	2008-06-20	2010-02-11	Bing-Yan Zhu	Triazolopyridine jak inhibitor compounds and methods
BRPI0910021A2 (pt)	2008-06-20	2015-09-01	Genentech Inc	"composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinas em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
WO2010010189A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010184A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	[1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
JO3041B1 (ar)	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010186A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010141796A2 (en)	2009-06-05	2010-12-09	Cephalon, Inc.	PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) *	2009-06-26	2014-12-01	葛萊伯格有限公司	用於治療退化性及發炎疾病之新穎化合物
WO2013173506A2 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
DK2863950T3 (en)	2012-06-22	2018-09-03	Galapagos Nv	AMINOTRIAZOLOPYRIDINE USED IN THE TREATMENT OF INFLAMMATION AND PHARMACEUTICAL COMPOSITIONS THEREOF

2010
- 2010-06-23 TW TW099120586A patent/TWI462920B/zh active
- 2010-06-24 AR ARP100102235A patent/AR077220A1/es active IP Right Grant
- 2010-06-25 RS RS20170532A patent/RS56035B1/sr unknown
- 2010-06-25 SG SG10201703497YA patent/SG10201703497YA/en unknown
- 2010-06-25 PL PL10724881T patent/PL2445911T3/pl unknown
- 2010-06-25 HU HUE10724881A patent/HUE033154T2/en unknown
- 2010-06-25 SG SG2011096211A patent/SG177363A1/en unknown
- 2010-06-25 GB GB1200457.8A patent/GB2483424B/en not_active Expired - Fee Related
- 2010-06-25 DK DK17152084.4T patent/DK3178819T3/da active
- 2010-06-25 UA UAA201200745A patent/UA107935C2/ru unknown
- 2010-06-25 SI SI201031962T patent/SI3178819T1/sl unknown
- 2010-06-25 SM SM20170265T patent/SMT201700265T1/it unknown
- 2010-06-25 ES ES10724881.7T patent/ES2626908T3/es active Active
- 2010-06-25 KR KR1020127001940A patent/KR101696669B1/ko active Active
- 2010-06-25 PL PL17152084T patent/PL3178819T3/pl unknown
- 2010-06-25 US US12/823,654 patent/US8088764B2/en active Active
- 2010-06-25 CN CN201410408911.8A patent/CN104262337A/zh active Pending
- 2010-06-25 KR KR1020187010516A patent/KR101916194B1/ko active Active
- 2010-06-25 SI SI201031467A patent/SI2445911T1/sl unknown
- 2010-06-25 PE PE2011002153A patent/PE20121032A1/es active IP Right Grant
- 2010-06-25 KR KR1020177000585A patent/KR101850716B1/ko active Active
- 2010-06-25 CN CN201080028631.4A patent/CN102482273B/zh active Active
- 2010-06-25 PT PT107248817T patent/PT2445911T/pt unknown
- 2010-06-25 WO PCT/EP2010/059064 patent/WO2010149769A1/en not_active Ceased
- 2010-06-25 AU AU2010264633A patent/AU2010264633B2/en active Active
- 2010-06-25 HR HRP20170826TT patent/HRP20170826T1/hr unknown
- 2010-06-25 DK DK10724881.7T patent/DK2445911T3/en active
- 2010-06-25 ME MEP-2017-122A patent/ME02699B/me unknown
- 2010-06-25 MX MX2011013450A patent/MX344951B/es active IP Right Grant
- 2010-06-25 EA EA201270075A patent/EA021637B1/ru unknown
- 2010-06-25 JP JP2012516761A patent/JP5591925B2/ja active Active
- 2010-06-25 LT LTEP10724881.7T patent/LT2445911T/lt unknown
- 2010-06-25 MY MYPI2011006263A patent/MY156664A/en unknown
- 2010-06-25 ES ES17152084T patent/ES2766573T3/es active Active
- 2010-06-25 MA MA34556A patent/MA33448B1/fr unknown
- 2010-06-25 BR BRPI1015569A patent/BRPI1015569B8/pt active IP Right Grant
- 2010-06-25 LT LTEP17152084.4T patent/LT3178819T/lt unknown
- 2010-06-25 PT PT171520844T patent/PT3178819T/pt unknown
- 2010-06-25 NZ NZ596838A patent/NZ596838A/en unknown
- 2010-06-25 CA CA2765985A patent/CA2765985C/en active Active
- 2010-06-25 EP EP10724881.7A patent/EP2445911B1/en active Active
- 2010-06-25 EP EP17152084.4A patent/EP3178819B1/en active Active
- 2010-06-25 HU HUE17152084A patent/HUE047478T2/hu unknown
2011
- 2011-11-29 IL IL216667A patent/IL216667A/en active IP Right Grant
- 2011-12-02 US US13/310,090 patent/US8563545B2/en active Active
- 2011-12-14 DO DO2011000388A patent/DOP2011000388A/es unknown
- 2011-12-20 ZA ZA2011/09386A patent/ZA201109386B/en unknown
- 2011-12-21 NI NI201100222A patent/NI201100222A/es unknown
- 2011-12-21 CL CL2011003247A patent/CL2011003247A1/es unknown
2012
- 2012-01-11 CR CR20120016A patent/CR20120016A/es unknown
- 2012-01-16 CO CO12005379A patent/CO6491040A2/es active IP Right Grant
- 2012-01-26 EC EC2012011626A patent/ECSP12011626A/es unknown
2013
- 2013-09-13 US US14/026,027 patent/US8999979B2/en active Active
2014
- 2014-07-30 JP JP2014154379A patent/JP2014221825A/ja not_active Withdrawn
2015
- 2015-04-02 US US14/677,058 patent/US9309244B2/en active Active
- 2015-08-28 AU AU2015218544A patent/AU2015218544B2/en active Active
2016
- 2016-04-11 US US15/095,317 patent/US9707237B2/en active Active
2017
- 2017-05-31 CY CY20171100569T patent/CY1119214T1/el unknown
- 2017-07-10 AU AU2017204744A patent/AU2017204744A1/en not_active Abandoned
- 2017-07-17 US US15/651,116 patent/US10328081B2/en active Active
2019
- 2019-05-09 US US16/407,593 patent/US11000528B2/en active Active
2020
- 2020-01-09 CY CY20201100020T patent/CY1122649T1/el unknown
- 2020-01-09 HR HRP20200033TT patent/HRP20200033T1/hr unknown
2021
- 2021-03-03 FR FR21C1011C patent/FR21C1011I2/fr active Active
- 2021-03-04 HU HUS2100007C patent/HUS2100007I1/hu unknown
- 2021-03-17 NL NL301096C patent/NL301096I2/nl unknown
- 2021-03-19 LT LTPA2021504C patent/LTC2445911I2/lt unknown
- 2021-03-23 NO NO2021013C patent/NO2021013I1/no unknown
- 2021-03-29 CY CY2008021C patent/CY2021008I2/el unknown
- 2021-04-14 US US17/230,483 patent/US12042498B2/en active Active
2024
- 2024-06-13 US US18/741,974 patent/US20240325405A1/en active Pending

Also Published As

Publication number	Publication date
DK3178819T3 (en)	2020-01-27
CA2765985C (en)	2017-06-06
UA107935C2 (xx)	2015-03-10
US20180000831A1 (en)	2018-01-04
JP2014221825A (ja)	2014-11-27
GB2483424A (en)	2012-03-07
US20150274722A1 (en)	2015-10-01
PL2445911T3 (pl)	2017-08-31
NO2021013I1 (no)	2021-03-23
KR20120107919A (ko)	2012-10-04
PT3178819T (pt)	2020-01-21
US20210369727A1 (en)	2021-12-02
KR101696669B1 (ko)	2017-01-16
US8563545B2 (en)	2013-10-22
KR20170007534A (ko)	2017-01-18
SI3178819T1 (sl)	2020-02-28
AR077220A1 (es)	2011-08-10
MX2011013450A (es)	2012-05-08
CY1122649T1 (el)	2021-03-12
EP2445911B1 (en)	2017-03-01
CN102482273A (zh)	2012-05-30
NL301096I1 (pt)	2021-03-24
RS56035B1 (sr)	2017-09-29
EP2445911A1 (en)	2012-05-02
CY1119214T1 (el)	2018-02-14
HRP20170826T1 (hr)	2017-08-25
HUE033154T2 (en)	2017-11-28
AU2015218544B2 (en)	2017-04-27
EP3178819B1 (en)	2019-12-04
DK2445911T3 (en)	2017-06-06
PE20121032A1 (es)	2012-08-25
CA2765985A1 (en)	2010-12-29
HRP20200033T1 (hr)	2020-03-20
ME02699B (me)	2017-10-20
KR101850716B1 (ko)	2018-04-20
LTC2445911I2 (lt)	2022-09-26
FR21C1011I2 (fr)	2022-03-25
CL2011003247A1 (es)	2012-04-13
NI201100222A (es)	2012-07-27
SG10201703497YA (en)	2017-06-29
CO6491040A2 (es)	2012-07-31
BRPI1015569B1 (pt)	2020-10-27
EA201270075A1 (ru)	2012-12-28
IL216667A0 (en)	2012-02-29
AU2010264633B2 (en)	2015-06-04
US10328081B2 (en)	2019-06-25
TW201103936A (en)	2011-02-01
SI2445911T1 (sl)	2017-07-31
LT2445911T (lt)	2017-06-12
CN104262337A (zh)	2015-01-07
US9707237B2 (en)	2017-07-18
US8088764B2 (en)	2012-01-03
HUS2100007I1 (hu)	2021-03-29
AU2015218544A1 (en)	2015-09-17
PL3178819T3 (pl)	2020-04-30
SG177363A1 (en)	2012-02-28
US8999979B2 (en)	2015-04-07
ES2766573T3 (es)	2020-06-12
MX344951B (es)	2017-01-12
FR21C1011I1 (pt)	2021-05-07
US20200078365A1 (en)	2020-03-12
ZA201109386B (en)	2012-08-29
LT3178819T (lt)	2020-01-27
US20120142678A1 (en)	2012-06-07
CY2021008I1 (el)	2021-05-05
US11000528B2 (en)	2021-05-11
PT2445911T (pt)	2017-06-12
KR20180041262A (ko)	2018-04-23
MA33448B1 (fr)	2012-07-03
US20140100220A1 (en)	2014-04-10
HK1167403A1 (en)	2012-11-30
NZ596838A (en)	2014-01-31
WO2010149769A1 (en)	2010-12-29
SMT201700265T1 (it)	2017-07-18
AU2017204744A1 (en)	2017-07-27
NL301096I2 (nl)	2021-04-12
LTPA2021504I1 (lt)	2021-04-12
EA021637B1 (ru)	2015-07-30
AU2010264633A1 (en)	2011-12-22
CN102482273B (zh)	2014-09-17
HUE047478T2 (hu)	2020-04-28
GB201200457D0 (en)	2012-02-22
CR20120016A (es)	2012-02-09
US9309244B2 (en)	2016-04-12
KR101916194B1 (ko)	2018-11-07
MY156664A (en)	2016-03-15
BRPI1015569B8 (pt)	2021-05-25
EP3178819A1 (en)	2017-06-14
CY2021008I2 (el)	2021-06-25
GB2483424B (en)	2012-07-18
US20100331319A1 (en)	2010-12-30
US12042498B2 (en)	2024-07-23
JP2012530766A (ja)	2012-12-06
ECSP12011626A (es)	2012-02-29
DOP2011000388A (es)	2012-04-15
US20160296530A1 (en)	2016-10-13
US20240325405A1 (en)	2024-10-03
TWI462920B (zh)	2014-12-01
JP5591925B2 (ja)	2014-09-17
IL216667A (en)	2015-08-31
ES2626908T3 (es)	2017-07-26

Publication	Publication Date	Title
BRPI1015569A2 (pt)	2016-08-16	compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0916862A2 (pt)	2016-02-10	compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BRPI1014759A2 (pt)	2016-04-19	composto útil para o tratamento de doenças degenerativas e inflamatórias
BRPI0816784A2 (pt)	2015-03-24	Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI1009920A2 (pt)	2016-03-15	composições bacterianas para profilaxina e tratamento de doença degenerativa.
BR112013014943A2 (pt)	2016-09-13	compostos úteis para o tratamento de aids
BRPI0908026A2 (pt)	2015-07-21	Métodos para o tratamento de doenças do intestino
CR11019A (es)	2009-10-20	3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI1013426A2 (pt)	2016-11-08	organismos para produção de 1,3-butanodiol
BRPI0716844A2 (pt)	2013-10-22	Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0921321A2 (pt)	2018-10-16	métodos para o tratamento de indwcções e tumores
BR112012001666A2 (pt)	2019-09-24	composições de proteína rsv f e métodos para fazer as mesmas
DK2504005T3 (da)	2014-01-13	Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
BRPI0911577A8 (pt)	2018-03-06	derivados espiro-indol para o tratamento de doenças parasíticas.
BR112012004836A2 (pt)	2019-09-24	pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI1007995A2 (pt)	2019-09-24	orto-aminoamidas para o tratamento de cãncer.
BRPI1009783A2 (pt)	2016-03-08	compostos para o tratamento de distúrbios metabólicos.
BRPI0813670A2 (pt)	2014-12-30	Compostos para tratamento
BRPI0912687A2 (pt)	2016-01-26	uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0818170A2 (pt)	2017-05-16	5-cianotienopiridinas para o tratamento de tumores.
BRPI0912412A2 (pt)	2016-07-26	compostos de pirazina fundidos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0912679A2 (pt)	2016-01-26	composição farmacêutica para o tratamento de fibromialgia
BR112012002267A2 (pt)	2016-11-08	compostos para o tratamento de inflamação.
BRPI0812105A2 (pt)	2014-11-25	Neramexano para o tratamento de nistagmo
BRPI0822292A2 (pt)	2015-06-30	Fármaco-alvo eficaz para o tratamento de tuberculose

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-04-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-05-21	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-12-10	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-05-05	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-09-08	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-10-27	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2025-04-15	B25A	Requested transfer of rights approved	Owner name: ALFASIGMA S.P.A. (IT)